Patents by Inventor Andreas Pfeifer
Andreas Pfeifer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100098707Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: December 11, 2006Publication date: April 22, 2010Applicant: AC Immune S.A.Inventors: Ruth Greferath, David Hickman, Andreas Muhs, Andrea Pfeifer, Nicolau Claude
-
Publication number: 20100080800Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.Type: ApplicationFiled: July 23, 2009Publication date: April 1, 2010Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20090238840Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis. In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in an organism, but particularly within an animal, particularly a mammal or a human, which is capable of preventing or alleviating amyloidosis, or the symptoms associated with amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD), including diseases or conditions characterized by a loss of cognitive memory capacity such as, for example, mild cognitive impairment (MCI).Type: ApplicationFiled: April 14, 2009Publication date: September 24, 2009Applicant: AC Immune, S.A.Inventors: Andrea Pfeifer, Claude Nicolau
-
Publication number: 20090155249Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.Type: ApplicationFiled: June 12, 2008Publication date: June 18, 2009Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20090093002Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.Type: ApplicationFiled: July 13, 2007Publication date: April 9, 2009Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20090017041Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: June 12, 2008Publication date: January 15, 2009Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20090017040Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins.Type: ApplicationFiled: June 12, 2008Publication date: January 15, 2009Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20080267986Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis. In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in an organism, but particularly within an animal, particularly a mammal or a human, which is capable of preventing or alleviating amyloidosis, or the symptoms associated with amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD), including diseases or conditions characterized by a loss of cognitive memory capacity such as, for example, mild cognitive impairment (MCI).Type: ApplicationFiled: December 12, 2006Publication date: October 30, 2008Inventors: Andrea Pfeifer, Claude Nicolau
-
Publication number: 20080166330Abstract: This invention relates to the treatment of atherosclerotic conditions through the inhibition of lipid oxidising abzymes by altering the composition of the intestinal microbial flora, for example by administering a bacterial composition to the individual. Suitable bacterial compositions may comprise, for example enteric bacteria such as lactobacilli spp, bifidobacteria spp, streptococcal spp and E. coli.Type: ApplicationFiled: November 1, 2005Publication date: July 10, 2008Inventors: Ivan Petyaev, Andrea Pfeifer
-
Patent number: 7294509Abstract: This invention relates to new immortalized human pre-adipose cell lines capable of differentiating into adipose cells and methods of obtaing the immortalized cells. In particular, the present invention pertains to immortalized pre-adipocyte cell lines derived from white adipose tissue and methods of producing the cell lines. The immortalized pre-adipocyte cells are capable of maturing into immortalized white adipose cells useful in developing drugs, food ingredients and supplements against obesity, diabetes and cardiovascular diseases.Type: GrantFiled: January 21, 2003Date of Patent: November 13, 2007Assignee: Nestec S.A.Inventors: Christian Darimont, Katherine Mace, Andrea Pfeifer
-
Publication number: 20070166311Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: December 11, 2006Publication date: July 19, 2007Inventors: Ruth Greferath, David Hickman, Andreas Muhs, Andrea Pfeifer, Claude Nicolau
-
Publication number: 20070071830Abstract: A primary composition that includes at least one lipophilic bioactive compound and a whey protein in an amount effective to increase the bioavailability of the lipophilic bioactive compound, and methods of forming the same. Also, an oral composition that contains the primary composition in a foodstuff, in a food supplement, in a cosmetic preparation or in a pharmaceutical preparation, and methods of forming the same.Type: ApplicationFiled: October 27, 2006Publication date: March 29, 2007Inventors: Karlheinz Bortlik, Francoise Saucy, Eliane Duruz, Myriam Richelle, Pierre Lambelet, Markus Baur, Andrea Pfeifer
-
Publication number: 20050106219Abstract: The invention relates to a primary composition in which at least one lipophilic bioactive compound is mixed with a whey protein, present in an amount effective to increase the bioavailability of the lipophilic bioactive compound. The invention also relates to an oral composition that contains the primary composition in a foodstuff, in a food supplement, or in a pharmaceutical preparation, and to a cosmetic preparation that contains the primary composition. Methods for increasing the bioavailability of the lipophilic bioactive compound and providing increased photostability and oxidation resistance are also provided.Type: ApplicationFiled: December 3, 2004Publication date: May 19, 2005Inventors: Karlheinz Bortlik, Francoise Saucy, Eliane Duruz, Myriam Richelle, Pierre Lambelet, Markus Baur, Andrea Pfeifer
-
Publication number: 20030175957Abstract: This invention relates to new immortalized human pre-adipose cell lines capable of differentiating into adipose cells and methods of obtaing the immortalized cells. In particular, the present invention pertains to immortalized pre-adipocyte cell lines derived from white adipose tissue and methods of producing the cell lines. The immortalized pre-adipocyte cells are capable of maturing into immortalized white adipose cells useful in developing drugs, food ingredients and supplements against obesity, diabetes and cardiovascular diseases.Type: ApplicationFiled: January 21, 2003Publication date: September 18, 2003Applicant: NESTEC S.A.Inventors: Christian Darimont, Katherine Mace, Andrea Pfeifer
-
Patent number: 6399381Abstract: Human epithelial colon immortalized cell line, which does not express tumour markers, which expresses metabolic markers specific for the non-immortalized human epithelial cells and metabolic differentiation markers specific for the non-immortalized epithelial cells of the human colon, and which is capable of adhering in vitro to the strain of lactic acid bacterium CNCM-1225. Serum-free culture medium characterized in that it comprises trace elements, vitamins consisting of vitamin C and retinoic acid, and hormones consisting of triiodothyronine, dexamethasone, hydrocortisone, bovine pituary gland extract, insulin, EGF and transferrin. Process for the immortalization of epithelial cells of the human colon, in which a culture of primary epithelial cells derived from the human colon is prepared, the culture is infected with a recombinant virus, the immortalized cells are cultured in the serum-free culture medium according to the invention.Type: GrantFiled: June 14, 2000Date of Patent: June 4, 2002Assignee: Nestac S.A.Inventors: Stéphanie Blum, Andrea Pfeifer, Yvonne Tromvoukis
-
Patent number: 6395542Abstract: Human epithelial colon immortalized cell line, which does not express tumour markers, which expresses metabolic markers specific for the non-immortalized human epithelial cells and metabolic differentiation markers specific for the non-immortalized epithelial cells of the human colon, and which is capable of adhering in vitro to the strain of lactic acid bacterium CNCM-1225. Serum-free culture medium characterized in that it comprises trace elements, vitamins consisting of vitamin C and retinoic acid, and hormones consisting of triiodothyronine, dexamethasone, hydrocortisone, bovine pituary gland extract, insulin, EGF and transferrin. Process for the immortalization of epithelial cells of the human colon, in which a culture of primary epithelial cells derived from the human colon is prepared, the culture is infected with a recombinant virus, the immortalized cells are cultured in the serum-free culture medium according to the invention.Type: GrantFiled: June 14, 2000Date of Patent: May 28, 2002Assignee: Nestec S.A.Inventors: Stéphanie Blum, Andrea Pfeifer, Yvonne Tromvoukis
-
Publication number: 20020012993Abstract: The present invention relates to improved continuous (immortalized) cell lines, in particular keratinocytes and melanocytes derived from normal human skin tissue. The present invention also relates to novel serum-free media for isolating, producing and maintaining said improved continuous keratinocyte and melanocyte cell lines. The present invention also relates to methods for producing primary melanocytes and keratinocytes under serum-free conditions without any feeder cells.Type: ApplicationFiled: June 19, 1998Publication date: January 31, 2002Inventors: MARKUS BAUR, CATHERINE MACE, ARMAND MALNOE, ANDREA PFEIFER, MARCELLE REGNIER
-
Patent number: 6194203Abstract: Immortalized adult human colon epithelial cell line, which does not express tumour markers, which expresses metabolic markers specific for the non-immortalized human epithelial cells and metabolic differentiation markers specific for the non-immortalized epithelial cells of the human colon, and which is capable of adhering in vitro to the strain of lactic acid bacterium CNCM-1225. Serum-free culture medium characterized in that it comprises trace elements, vitamins consisting of vitamin C and retinoic acid, and hormones consisting of triiodothyronine, dexamethasone, hydrocortisone, bovine pituary gland extract, insulin, EGF and transferrin. Process for the immortalization of epithelial cells of the human colon, in which a culture of primary epithelial cells derived from the human colon is prepared, the culture is infected with a recombinant virus, the immortalized cells are cultured in the serum-free culture medium according to the invention.Type: GrantFiled: April 17, 1997Date of Patent: February 27, 2001Assignee: Nestec S.A.Inventors: Stéphanie Blum, Andrea Pfeifer, Yvonne Tromvoukis